Is this Hikma's cue for a break out?Will Hikma break out after a 5 year H&S pattern,
now that it's making progress in the Covid-19 vaccine business?
Pharmaceuticals
AB=CD Pattern Replacement to Catch the TrendAURO Pharma is on marathon but a sprint marathon exhausts the athlete and the same happens to the stocks. AB=CD pattern would make the point D- a point of in flexion and fall all the way to POC level marked, from where again a buying opportunity can be tapped by the incumbent buyers and from the initiative buyer looking for a discounted entry .
Ajantha Pharma gave a clear Breakout in Daily ChartAFTER FANTASTIC EARNINGS
AJANTHA PHARMA GAVE A GOOD BREAKOUT AND FOR SURE SUSTAINABLE BREAKOUT.
CMP 1629
TARGET 1800
SL- 1566
TIME- 1 WEKK HOLDING
SUNPHARMA awakens from slumber.Well, atleast the charts say so.The stock on the weekly horizon is making an Inverted Head and Shoulders, the target for which comes to be about 680 odd levels. On the daily horizon, the stock is well above the key EMAs. Besides, the price shows no divergence with respect to the RSI and Stochastics.
This post is solely for education purpose.
Ajanta pharmaHello!! its Ajanta pharma now...... mmmm I personally don't like pharma stocks much but this looks good and it is in a rangebound condition for now and the red bold red lines are very good resistances and supports ....... if it breaks the resistance some rally of 100-200 pt.s can be seen. #my_view #learner
PFE - 1H - 21.07.2020#PFE - 1H - MACD divergece already descounted?
Notable divergence on our 1H MACD. The key question here is that if has been already discounted on the last bullish run from 31 USD to 36 USD?
Today we have reach an importan resistance on 37 USD level. If there is not any news about COVID vaccine among these days, we will have a healthy correction of the price during the rest of the week.
PFIZER Long Why: Weekly Bearshirsh pattern break.
Risk:reward:-1:2
StopLoss:3970
Target:4180
Target2:4350
Why I am Long on $MMEDFRight now one of the stocks that have my attention, (partly because of Kevin O'Leary) and the rest of its history is Mind Medicine (MindMed Inc.) They are one of the first companies finding a way to neutralize LSD while working on a DMT based therapy drug. Also, the market cap and entry is low. This is one of those stocks where you need to dig deep into the pitch deck and look at competition, market opportunities, and entry price. Right now as a biotech company, it is one of my favorite low priced biotech stocks, and as a long hold in somebody's portfolio, I don't think the risk aversion is too high. That being said, everything I say is on an opinion based basis. Please proceed with caution and invest at your own risk. Do your own due diligence.
Biogen trend line to watchBiogen today reported a huge earning beat, but disappointing guidance for the rest of the year. When you crunch the numbers, the midpoint of Biogen's guidance range for 2H 2020 came in slightly below Street consensus for both earnings and revenues.
Biogen has a reasonable, but not great valuation, with forward PEG of 3.78 and forward PSG of 1.27. It's currently in the lower half (26th percentile) of its three-year valuation range in terms of forward P/S and forward P/E. Biogen pays no dividend, and as a result the stock is more volatile than a dividend-paying stock would be.
Sentiment on Biogen improved quite a bit today. There have been no analyst upgrades yet, but options traders moved from net-bearish to net-bullish positioning for the short term, and from net-bearish to net-neutral positioning for the long term.
We're coming up on the strong season for pharmaceutical stocks in August. Biogen has only one phase 2 clinical trial result due in the second half of 2020 for its multiple sclerosis drug, but there are five results due in the first half of 2021, including a phase 3. These could prove to be major catalysts for the stock over the next year.
For the near term, watch for a possible trend line break as a sign that the stock will move higher.
ABBV buy the dip ahead of pharma seasonAbbvie's volume has slackened somewhat after its recent triangle breakout, and it has broken its steep upward trendline. We may see a small correction late this month as Abbvie pulls back toward triangle top. However, if healthcare and pharmaceutical sector earnings continue to deliver this month (as they have so far), then Abbvie should get some buying volume along with the rest of the sector.
And then in August, a period of seasonal pharmaceutical strength begins. In The Stock Traders' Almanac, Jeffrey Hirsch makes an extensive study of seasonal stock market performance by sectors. His third-best-performing seasonal trade by average 10-year return (16.8%) is to go long biotech from early August to early March. I believe that's because this is the busy season for FDA drug application reviews.
The pharma sector does have an unusual level of political risk this year. Democrats have traditionally been hard on the pharma sector, and they look poised this year for a sweep. If the polls remain strongly blue, then we might see pharma underperform this year.
That said, I think a lot of the political risk is already priced in. Whereas most of the stocks I look at are at the very top of their 3-year valuation range in terms of forward earnings and sales, pharmaceutical companies like Abbvie and Merck are trading in the bottom quartile of their 3-year valuation range. With forward PEG ratio around 2, forward PSG ratio around 0.5, and a whopping 5% dividend, Abbvie looks really attractively valued. I've been doing a lot of deal-hunting lately, and this is one of the only stocks I've seen with both a strong growth story and a valuation I really like. The analysts and options traders like it too; Abbvie has a 9.9/10 Equity Starmine Summary Score, and near-dated options positions are heavily skewed toward calls.
Vanda Pharmaceuticals! Earnings 40% Trade!!FA:
Earings release- the last earnings where the estimate was higher than 0.05 per share it led to the stock rallying by 40%- unless, the earings surprise is a negative one; we can expect a rally from Vanda Pharmaceuticals.
TA:
Currently been trading in a limited channel- lack of momentum could lead to a dump if earnings estimate is negative or perhaps mean no rally even if the earnings estimate is positive.
Watch out for the resistance, it is unlikely to take it out in these market conditions.
-Megalodon Whales (Rahim)
Enjoyed Charting this for you all,Please SHARE/LIKE/COMMENT and you are welcome to give your feedback or post your own charts below :)
NASDAQ:VNDA FWB:VM4
Abbot Laboratories $ABT "Cup"$ABT is forming cup needs to hold above $100 for a confirmation. watch for a heavy volume as well
12 months Consensus Price Target: $103.67
if you find my charts useful, please leave me "like" or "comment".
Please don't trade according to the ideas, rely on your own knowledge.
Thx
Santen Analysis SNPHYFormations drawn
Rising Wedge
Scythe
I expect a breakdown of this weird wedge that has formed between a major trendline and a line of strong bounce areas
EQ Watch for Resistance Breakout. Bullish FridayEQ reached top mover status as a gainer one day and a loser the following day.
Thursday, EQ was up +1.49% pre-market.
I predict stock moves at a steady pace toward $24 price target.
EQ is a mall biotech company researching Alzheimer's medicine.
Healthcare is our third-largest sector ($6.2 T).
Financials ($7.53 T) ranks second and information technology ($9.58 T) first.
Please always do your own research.
This is not advice.
I'm here to learn.
Thoughts?
$MRNA WatchYet another potentially profitable play regarding the Covid-19 pandemic is $MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy in level is at $61-$63 and because of its heavy reliance on the performance of its vaccine to remain profitable I am keeping a tight stop loss. Anything over a 10% drop presents to much risk to feasibly call it worthwhile.
A very good potential pharma company to invest for good returns.One can trade in this script with immediate target of 570 followed by 610 and higher before stock split, keep stop loss at 500. Good luck and have a great profitable day.
For long term investors keep it in your portfolio and hold for multi fold returns.
for more you can visit my site 5nancial.blogspot.com
VXRT was a top quarterly gainer, rising +376.19%. Expect UptrendVaxart (VXRT, $8) was one of top quarterly gainers, jumping +376.19% to $8 per share. Tickeron A.I.dvisor analyzed 174 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 155 of them (89.09%) charted an Uptrend while 19 of them (10.91%) trended down. Tickeron A.I.dvisor found 135 similar cases when VXRT's price went up 15% within three months. In 83 out of those 135 cases, VXRT's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for VXRT are 61%.
VXRT in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on June 30, 2020
This price move signals that VXRT may fall back below the higher band and head toward the middle band. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 37 of 42 cases where VXRT's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 88%.
GLENMARK 01 JULY 2020GLENMARK 01 JULY 2020
SHORT-SELL 2/3 LOT OF GLENMARK @ 430
Dear traders kindly follow our signals for maximum profits, our signals are based on analytics, algorithms, mathematical derivatives.
Always be a responsible trader, kindly trade only when you have maximum opportunity in the market with minimum risk and with keynotes like data,analysis and proper strategies.
Kindly message me for profit making signals and trades.
Dear traders kindly follow our signals for maximum profits, our signals are based on analytics, algorithms, mathematical derivatives.
Always be a responsible trader, kindly trade only when you have maximum opportunity in the market with minimum risk and with keynotes like data,analysis and proper strategies.
Kindly message me for profit making signals and trades.
Pfizer: Strong Sell Opportunity.PFE continues to underperform on the long-term and under the recent fundamentals the pressure on it is growing. The Bearish Megaphone on 1D (RSI = 33.977, MACD = -1.120, ADX = 56.370) has printed a bearish continuation sequence that extends at least towards the 27.90 Support.
** If you like our free content follow our profile to get more daily ideas. **
Comments and likes are greatly appreciated.
NKTR was a top gainer, rising +40.26%. Expect Uptrend reversalNektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended down.My A.I.dvisor found 426 similar cases when NKTR's price went up 15% within three months. In 218 out of those 426 cases, NKTR's price went down during the following month. Based on these historical data, my A.I. thinks the odds of an Uptrend reversal for NKTR are 51%.
BHVN Aroon Indicator entered an Uptrend on June 19, 2020A buy signal is generated. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. I backtested this indicator and found 162 similar cases, 149 of which were successful. Based on this data, the odds of success are 90%.
